CV Therapeutics (Nasdaq: CVTX) Upgraded to BUY by Independent ... 12.12. / 14:46
NANUET, N.Y., Dec. 12 /PRNewswire-FirstCall/ -- White Mountain Capital, a provider of independent research on select biotechnology companies, today upgraded its rating of CV Therapeutics to BUY from its initial HOLD rating issued in October.
"The recent decline in stock price resulting from the FDA``s review of ranolazine makes this a significantly undervalued company at these levels," said Oren Levy, M.D., Ph.D., the Director of Biotechnology Research at White Mountain Capital. "We believe that ranolazine will still reach the market, gaining regulatory approval in 2006. We think the current stock price reflects the needed additional trials."
Dr. Levy said that despite the company``s missteps in communicating with the investment community, CV Therapeutics is an excellent company with three promising drug candidates, ample financial resources and a capable management team.
For a copy of the report, call toll-free 866-833-5300 during market hours. For more White Mountain Capital research titles, visit http://www.whitemountaincapital.com/.
|aus der Diskussion:||+++ CV Therapeutics Inc (CVTX) - Kurssturz +++|
|Autor (Datum des Eintrages):||seinfeld (12.12.03 23:23:25)|
|Beitrag:||106 von 470 (ID:11590746)|
|Alle Angaben ohne Gewähr © wallstreet:online|